United Therapeutics Corporation (UTHR) Free cash flow 2016–2025
United Therapeutics Corporation (UTHR) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
$1.0BFY2025 · since FY2016: $605.6M → $1.0B
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $1.0B | -3.7% |
| FY2024 | $1.1B | +44.5% |
| FY2023 | $747.6M | +12.6% |
| FY2022 | $663.7M | +39.0% |
| FY2021 | $477.4M | -31.4% |
| FY2020 | $696.4M | +339.9% |
| FY2019 | -$290.3M | -148.9% |
| FY2018 | $594.0M | +53.1% |
| FY2017 | $387.9M | -35.9% |
| FY2016 | $605.6M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More UTHR financial trends
UTHR RevenueUTHR Net incomeUTHR Net marginUTHR Gross profitUTHR Gross marginUTHR Operating incomeUTHR Operating marginUTHR Operating cash flowUTHR Capital expendituresUTHR Return on equityUTHR Stock buybacksUTHR Dividends paidUTHR Total assetsUTHR Total liabilitiesUTHR Shareholders’ equityUTHR overview →